MetLife Investment Management LLC Has $4.30 Million Stock Position in Masimo Co. (NASDAQ:MASI)

MetLife Investment Management LLC increased its position in Masimo Co. (NASDAQ:MASI - Free Report) by 9.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,026 shares of the medical equipment provider's stock after buying an additional 2,214 shares during the period. MetLife Investment Management LLC's holdings in Masimo were worth $4,302,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. FMR LLC grew its stake in Masimo by 19.8% in the fourth quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider's stock valued at $1,338,509,000 after acquiring an additional 1,340,836 shares during the period. Vanguard Group Inc. grew its position in Masimo by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider's stock valued at $758,182,000 after purchasing an additional 66,215 shares during the period. Capital Research Global Investors increased its stake in Masimo by 80.5% during the 4th quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider's stock valued at $405,807,000 after purchasing an additional 1,094,647 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Masimo by 119.0% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider's stock worth $286,823,000 after buying an additional 943,001 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its stake in shares of Masimo by 1,276.9% in the fourth quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider's stock valued at $156,604,000 after buying an additional 878,587 shares in the last quarter. 85.96% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares of the company's stock, valued at approximately $2,754,601.53. This trade represents a 11.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Bilal Muhsin sold 30,000 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares in the company, valued at $4,048,568.28. This represents a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 9.70% of the company's stock.

Masimo Stock Performance

Shares of MASI opened at $162.63 on Friday. The stock has a 50 day moving average of $166.04 and a 200 day moving average of $165.25. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo Co. has a 12 month low of $101.61 and a 12 month high of $194.88. The company has a market capitalization of $8.79 billion, a price-to-earnings ratio of 112.16 and a beta of 1.28.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. The company had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. As a group, sell-side analysts forecast that Masimo Co. will post 4.1 earnings per share for the current year.

Analyst Ratings Changes

MASI has been the topic of a number of analyst reports. Piper Sandler upped their target price on shares of Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a research report on Thursday, April 10th. Raymond James increased their price target on Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research report on Friday, December 27th. Finally, Wells Fargo & Company lifted their price objective on shares of Masimo from $193.00 to $205.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Masimo currently has an average rating of "Moderate Buy" and a consensus target price of $194.80.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.